The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 06, 2021

Filed:

Jul. 29, 2019
Applicant:

Immunomedics, Inc., Morris Plains, NJ (US);

Inventors:

Serengulam V. Govindan, Summit, NJ (US);

David M. Goldenberg, Delray Beach, FL (US);

Assignee:

Immunomedics, Inc., Morris Plains, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4745 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 31/675 (2006.01); C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61K 31/713 (2006.01); A61K 31/454 (2006.01); C07K 16/28 (2006.01); A61K 31/337 (2006.01); A61K 31/4375 (2006.01); A61K 31/513 (2006.01); C07K 16/32 (2006.01); A61K 31/7088 (2006.01); A61K 31/4184 (2006.01); A61K 31/00 (2006.01); A61K 31/502 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61B 6/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4745 (2013.01); A61K 31/00 (2013.01); A61K 31/337 (2013.01); A61K 31/4184 (2013.01); A61K 31/4375 (2013.01); A61K 31/454 (2013.01); A61K 31/502 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/675 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 39/39558 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61K 47/6853 (2017.08); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3007 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3061 (2013.01); C07K 16/3092 (2013.01); C07K 16/32 (2013.01); A61B 6/481 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. The ADC may be administered at a dosage of between 4 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, most preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the ADC is administered in combination with one or more other therapeutic agents, such as a PARP inhibitor, a microtubule inhibitor, a Bruton kinase inhibitor or a PI3K inhibitor. Most preferably, the ADC is of use for treating a Trop-2 expressing cancer, such as metastatic urothelial cancer.


Find Patent Forward Citations

Loading…